Felicity Thomas

OSD forms are popular within the industry due to the various advantages they offer, but there are specific considerations required to get the best OSD form possible.

As compounds become more complex in nature and biological ingredients are more widely used, stability testing approaches must follow suit and provide flexibility for developers.

Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.

A brief overview of three notable cases of adverse drug reactions.

Despite increasing R&D budgets by bio/pharma companies, returns on this investment are reducing and the cost of bringing an asset to market is increasing.

Metrology has the potential to not only prevent harm to patients but also to support innovative therapeutic options.

Outsourcing stability testing to full-service providers can offer comprehensive benefits to bio/pharma companies.

The huge potential of biopharma is presenting an important epoch for outsourcing partners that can support the development and manufacture of biologics in an efficient way.

As compounds become more multifaceted and biological ingredients are more commonly utilized, stability testing tactics must follow suit and ensure flexibility for developers.

Metrology has the potential to not only avoid damage to patients but also to encourage novel therapeutic opportunities.

Amid the rapidly rising cases of a novel coronavirus, concerns are being raised over preparedness and potential disruptions to the pharma supply chain.

Lipid-based solutions offer a natural approach to improving the solubility of cannabinoid-derived products.

As cell and gene therapies become more prominent, industry is seeking the expertise and capabilities of outsourcing partners to ensure success.

Drug companies will have to sharpen their understanding of evolving E&L regulatory expectations in order to remain compliant.

Biologics raise unique formulation and development challenges, and industry is still on a learning curve to get the best out of these diverse and complex therapies.

As a new decade has begun, this editorial reviews some of the biggest, brightest, and boldest happenings from the industry over the past 10 years.

Regulatory mandates, niche diseases, and patient-centric solutions have all impacted pharma packaging over the years and are expected to help shape the future of the sector.

PTE looks ahead to 2020’s edition of Pharmapack-the pharma industry’s dedicated packaging and drug delivery event.

Without careful consideration and understanding, new regulations for medical devices could lead to the withdrawal of combination products from the market.

As the UK heads to the polls for an unusual December general election, industry issues manifestos on medicines while Europe rejoices some movement … finally.

Spray drying is a versatile and rapid technique that can provide companies with a suitable and scalable option to improve the solubility and bioavailability of drug products.

As regulatory bodies extend the oversight of E&L testing, companies working with drug products need to make provisions on how to best comply with the evolving expectations.

Industry experts examine the fundamentals of dissolution testing, including challenges resulting from an increasing number of poorly soluble molecules under development in the pharmaceutical pipeline.

After years of discussions around pricing, UK governmental bodies and Vertex have finally reached an agreement on cystic fibrosis treatments.

Palatability is crucial for adherence and compliance to oral drug regimens.

A complete understanding of primary packaging physicochemical properties is necessary in the formulation and development of biologics.

With no plausibly approvable deal on the table in the UK government at the moment, it is possible that Brexit could be extended even further.

In this article, experts discuss the fundamentals of dissolution testing and highlight the challenges that are surfacing as a result of the increasing numbers of poorly soluble molecules entering the development pipeline.

Lipid-based formulations provide a versatile solution to bioavailability issues, but a multi-disciplinary approach is needed to overcome limitations with poorly soluble compounds.

As the development pipeline becomes more saturated with complex molecules and patient experience becomes more important, developers are looking to outsourcing partners to provide more specialized expertise and solutions.